Monthly Archives: May 2006

How Many is Too Many? Off-Label Uses and RX Drugs

Posted on May 10, 2006 by Mark Senak

There was a lot of coverage as well as sturm and drang about a study published by the Archives of Internal Medicine regarding the off-label use by prescribers of medications.  According to the report, there should be further study to … Continue reading →

Posted in Uncategorized | 1 Comment

Is the Bargain Worth the Price?

Posted on May 9, 2006 by Mark Senak

There is good news for the pharmaceutical company image.  For the second year in a row, the Harris Interactive ranking of companies shows a definite improvement for the industry.  The measure has historically been volatile.  However, also this week, concerns … Continue reading →

Posted in Pharma Industry Image | 2 Comments

FDA Launches Investigation of FDA

Posted on May 8, 2006 by Mark Senak

The FDA announced on Friday that it was initiating an assessment of the new drug review process.  This, needless to say, is going to be tricky. According to the FDA press release, this review will be led by senior management … Continue reading →

Posted in FDA Policy | Comments Off on FDA Launches Investigation of FDA

Weekly Roundup – 5/5/06

Posted on May 5, 2006 by Mark Senak

Ok Partners, it is time for the weekly roundup.  Court Rules Terminal Patients Have Right to Access Drugs – A federal court ruled that terminal patients may have a right to access drugs that have cleared Phase I studies but … Continue reading →

Posted in Weekly Roundup | Comments Off on Weekly Roundup – 5/5/06

Statins and The RX to OTC Switch Pipeline

Posted on May 4, 2006 by Mark Senak

As mentioned yesterday, the increase in the number of patent expirations set for the next few years indicates an opportunity for an increase in RX to OTC switches.  In March, I had a posting on the challenges in the current … Continue reading →

Posted in OTC Switches | 3 Comments